指南与共识膀胱癌与上尿路尿路上皮癌

指南风险分层再分期电切对高级别Ta期尿路上皮癌BCG治疗结局的影响

Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes.
指南 / 共识 · Eur Urol Oncol · 2021-04-29

该研究回顾性分析了209例接受足量BCG治疗的高级别Ta期膀胱癌患者,其中104例(50%)行再分期电切。再分期电切与改善的无进展生存(p=0.050)和无复发生存(p=0.003)相关;在同时符合AUA和EAU再分期指征的高危患者中,未行再分期与复发风险增加超过两倍相关(67% vs 15%,p=0.002)。结论支持对所有高级别Ta期病变行再分期电切。

要点

  • 再分期电切在全部高级别Ta期患者中与更好的无复发生存相关(p=0.003)。
  • 同时符合AUA和EAU再分期指征者,未再分期复发率67% vs 15%(p=0.002)。
  • 仅1%患者再分期时升级为pT1,但再分期仍改善结局。

核心结论

  • 对所有高级别Ta期患者行再分期电切与改善的结局相关,无论风险分层如何。
  • 再分期电切的获益在同时符合AUA高危标准(大、多发病灶)和EAU标准(固有肌层缺失)的高危患者中最显著。
  • 数据支持对全部高级别Ta期病变采用非风险适应性的再分期电切策略。

研究设计与样本

  • 机构回顾性研究,纳入2000至2019年接受足量BCG治疗的高级别Ta期膀胱癌患者209例。
  • 104例(50%)行再分期电切,其中39例(38%)发现残留病变,仅1例(1%)升级为pT1。
  • 采用Kaplan-Meier法估计生存,Cox回归和log-rank检验分析变量与生存的关联。

主要发现

  • 在全部未分层高级别Ta期患者中,再分期电切与改善的无进展生存相关(p=0.050)和无复发生存相关(p=0.003)。
  • 基于AUA指南行再分期电切者5年无复发生存为73%(95%CI 63-81%),未行者为52%(95%CI 40-62%)。
  • 基于EAU指南行再分期电切者5年无复发生存为76%(95%CI 61-86%),未行者为22%(95%CI 4-49%)。
  • 在45例同时符合AUA高危标准和EAU标准(固有肌层缺失)的患者中,未行再分期与复发风险增加超过两倍相关(67% vs 15%,p=0.002),与进展风险增加相关(25% vs 6%,p=0.109)。

关键数值与推荐

  • AUA再分期电切指征包括大肿瘤和多发病灶。
  • EAU再分期电切指征包括初次标本中固有肌层缺失。
  • 同时符合上述两项标准的患者未行再分期时复发率67% vs 15%(p=0.002)。

临床怎么用

  • 对于高级别Ta期膀胱癌接受BCG治疗的患者,应考虑行再分期电切以改善无复发生存和无进展生存。
  • 尤其对于具有大肿瘤、多发病灶或初次标本固有肌层缺失的高危患者,再分期电切的获益更为明显。
  • 研究结果支持不按风险分层而对所有高级别Ta期病变行再分期电切。

局限性

  • 研究为回顾性设计,存在选择偏倚,且未对选择再分期电切的候选者进行未测量混杂因素的校正。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guideline indications for restaging transurethral resection (reTUR) for high-grade (HG) Ta bladder tumors vary due to a paucity of data. OBJECTIVE: To investigate guideline-based, risk-adapted approaches to reTUR for HG Ta lesions. DESIGN, SETTING, AND PARTICIPANTS: An institutional review of HG Ta patients who received adequate bacillus Calmette-Guérin (BCG) from 2000 to 2019 was conducted. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Guideline criteria for reTUR were used to stratify patients. Kaplan-Meier product limits estimated survival. Cox regression and log-rank tests identified association of variables with survival. RESULTS AND LIMITATIONS: Of the 209 patients with HG Ta bladder cancer, 104 (50%) underwent reTUR, which identified residual disease in 39 patients (38%). Only one patient (1%) was upstaged to pT1 on reTUR. In all unstratified HG Ta patients, reTUR was associated with improved progression-free survival (p = 0.050) and recurrence-free survival (RFS; p = 0.003). The 5-yr RFS for patients who underwent versus those who did not undergo reTUR based on AUA guidelines was 73% (95% confidence interval 63-81%) versus 52% (40-62%), and for those who underwent versus those who did not undergo reTUR based on EAU guidelines was 76% (61-86%) versus 22% (4-49%). In 45 patients meeting both AUA high-risk criteria (large, multifocal tumors) and EAU criteria (lack of detrusor muscle) for reTUR, lack of restaging was associated with over a two-fold increase in recurrence (67% vs 15%, p = 0.002) and progression (25% vs 6%, p = 0.109). Data were limited by selection bias unaccounted for in selecting candidates for reTUR. CONCLUSIONS: Restaging TUR in all HG Ta patients, regardless of risk stratification, was associated with improved outcomes. The benefit of reTUR was most notable in high-risk patients without muscle in the index specimen, consistent with components of both AUA and EAU guidelines. These data support a non-risk-adapted approach to reTUR for all HG Ta lesions. PATIENT SUMMARY: Restaging bladder tumor resection improves outcomes in patients with high-grade Ta tumors treated with bacillus Calmette-Guérin (BCG).

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Hensley PJ, Bree KK, Brooks N, et al. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. Eur Urol Oncol. 2021. PMID: 33935020. doi:10.1016/j.euo.2021.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。